Fritextsökning
Innehållstyper
-
ZEISS är redo för Elmia Verktygsmaskiner
Du kan få en demonstration av mätmaskinen ZEISS CONTURA.
-
Samuel Lagercrantz: “Companies that do this successfully will take the lead”
The development of new medicines and medical technologies should not focus too narrowly on prolonging life. It is equally important to develop treatments that r...
-
Advancing 3D Culture Imaging: Insights from Academia, Biotech, and Pharma
Webinar | March 13, 2024, 12 PM EST.
-
“Life science is important on a personal level”
From the High Coast to the Government Offices. Jeanette Edblad is a native of Ångermanland, and since September last year, she has been Head and Coordinator of ...
-
Don't miss ZEISS Quality Innovation Days
Digital event April 15-19, 2024.
-
Why the world renown researcher Marc Tessier-Lavigne resigns as Stanford´s president
In mid-summer, neuroscientist Marc Tessier-Lavigne announced his resignation as President of Stanford following allegations of manipulated study data. According...
-
Join the premier metrology and quality assurance event of the year
ZEISS QUALITY INNOVATION SUMMIT in Berlin, October 22-24, 2024.
-
The new ZEISS Celldiscoverer 7 has been launched
Adaptable automation for advanced workflows.
-
Life science trends 2025 – The economy
Upcoming patent expirations are driving pharmaceutical companies to acquire in 2025. In Sweden, we may be on our way to brighter times and fewer bankruptcies. T...
-
Who pays for Rebecca Doe – and all of us?
Anna Törner on how easily we get used to the idea that healthcare is free - when it really is about how and who pays for it
-
The dock that “thinks” for itself
The world of bulk material handling seems straightforward at first glance: moving, filling, delivering. However, the art of dealing with a variety of different ...
-
Bioarctic i miljardavtal med läkemedelsjätte
Det svenska alzheimerbolaget Bioarctic licensierar ut kommersialisering och utveckling av två antikroppar till den globala läkemedelsjätten Bristol Myers Squibb.
-
Index rekommenderas avsluta studie: ”Överraskande och nedslående”
En oberoende kommitté rekommenderar Index Pharmaceuticals att avbryta sin fas III-studie med läkemedelskandidaten Cobitolimod, som prövas som behandling mot ulc...
-
Study: Popular diabetes drug may be effective against liver disease
After its success in diabetes and weight loss, a new potential therapeutic area has been identified for Ozempic and other GLP1 analogues. A new study links the ...
-
Xbrane i licensavtal med indisk generikajätte – ”Den perfekta partnern”
Biosimilarutvecklaren Xbrane Biopharma och indiska Intas Pharmaceuticals har ingått ett licens- och samutvecklingsavtal.
-
Ingrid Lönnstedt: Demystification of the power of a scientific study
”You surely do realize that even the smallest changes in study assumptions may influence the estimated sample size needed. And how is it even possible to guess ...
-
Total pipeline of pharmaceutical companies reaches a record high – 22,921 medicines are currently being developed
Despite the difficult economic times, pharmaceutical companies have never developed as many new drugs as now.
-
Study names with an attitude – more important than you might think
Ironman, T-rex, Star-Trek. Popcorn, Proper, Scout. Nope, these are neither fantasy films nor dog names. They’re the names of ongoing cancer studies in Sweden.
-
Eternal Rye – Improving Plant Breeding Methods
User story from Martin Luther University Halle.
-
Swedish Healthtech Company 1928 Pushing Forward
The full service analytics platform is expanding the business.
-
A new special edition and a new event in Copenhagen – This is happening at Life Science Sweden 2024
The new year brings new features for the readers of Life Science Sweden.
-
From Valneva to the CEO position at NorthX – “I saw it as a great opportunity”
A new cell therapy for leukaemia, a vaccine in tablet form against cholera, and a proprietary mRNA line with the potential capacity to supply the entire Nordic ...
-
Saving lives worldwide with low-cost molecular diagnostics
High throughput testing for many upper respiratory tract pathogens thanks to automation technology
-
Her company is developing a new tablet form obesity drug
Obesity and diabetes are the primary targets of a new tablet treatment under development by Malmö-based Pila Pharma. The company’s ambition is to take on the bi...
BREAKING